Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
TAVR
MedTech
FTC aims to stop Edwards’ acquisition of JenaValve
The FTC moved to block Edwards Lifesciences’ buyout of JenaValve and its heart implant for aortic regurgitation, slated for FDA approval this year.
Conor Hale
Aug 7, 2025 11:33am
Abbott eyes structural heart gains after Boston Scientific exit
Jul 17, 2025 1:00pm
Boston Scientific pulls Acurate TAVR implants from market
May 28, 2025 11:01am
FDA approves Edwards TAVR for patients before they show symptoms
May 1, 2025 12:56pm
Edwards highlights 8-year durability data for its Resilia valves
Apr 18, 2025 11:30am
Abbott completes first-in-human balloon-expanded TAVR procedures
Nov 25, 2024 1:30pm
